Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause
Closed for comments This consultation ended on at Request commenting lead permission
3 Committee considerations
The evidence
3.1 NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This rapid review did not identify any relevant studies.
3.2 The professional experts and the committee considered the key efficacy outcomes to be: quality of life outcomes including menopause-specific questionnaires and endocrine function of the implant (including the levels of oestrogen, progesterone and follicle stimulating hormone) in the short and long term.
3.3 The professional experts and the committee considered the key safety outcomes to be: laparoscopy-related complications (including pain, bleeding, and infection), reduced fertility (in the period between ovarian tissue removal and reimplantation), and premature menopause.
3.4 Patient commentary was sought but none was received.
Committee comments
3.5 There was no published evidence for the use of this procedure in otherwise healthy people who wanted to prevent menopause symptoms.
3.6 This guidance is specifically to prevent menopause symptoms in otherwise healthy people. It does not cover the use of this procedure to preserve fertility or to prevent menopausal symptoms or premature menopause from iatrogenic (such as cancer treatment) or non-iatrogenic (such as hereditary or disease) causes.
3.7 The committee was informed that pharmacological hormone replacement therapy (HRT) has an established efficacy and safety profile for preventing the symptoms of menopause.
3.8 The committee was informed that there is a small risk of significant complications associated with laparoscopy.
Colin Howie
Vice-chair, interventional procedures advisory committee
March 2022
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions